Rigel Pharmaceuticals
Nasdaq RIGL · South San Francisco, CA
Works in Hematology · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Oncology · Respiratory
Rigel Pharmaceuticals is a clinical trial sponsor based in South San Francisco, CA, listed as Nasdaq RIGL. It has 5 active clinical trials with 264 planned participants, across 7 therapeutic areas. Since 2021 it has completed 4 trials and stopped 1 early.
Trial track record · since 2021
Financials · Nasdaq RIGL
Pipeline · 5 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
4 approved drug applications with a product on the market.
Questions about Rigel Pharmaceuticals
Rigel Pharmaceuticals is lead sponsor of 5 active clinical trials on ClinicalTrials.gov, with 264 planned participants, in Hematology, Immunology, Infectious disease, Metabolic & endocrine and other areas. Since 2021 it has completed 4 trials and stopped 1 early.
Rigel Pharmaceuticals is based in South San Francisco, CA and is listed as Nasdaq RIGL. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Rigel Pharmaceuticals; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-01.
Approve Suite is not affiliated with Rigel Pharmaceuticals.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.